Market Overview

UPDATE: Sterne Agee Downgrades PAREXEL Following FY13 Results, FY14 Guidance

Share:
Related PRXL
Jefferies Boosts Targets Across Pharmaceutical Service Stocks
Jefferies Previews Booming Biotech Earnings

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan downgraded PAREXEL (NASDAQ: PRXL) from Neutral to Underperform, and lowered the price target from $44.00 to $36.00.

In the report, Sterne Agee noted, “After rigorous yet straightforward analyses, we conclude that PRXL's FY13 results were inflated by several favorable, non-fundamental variables and that FY14 operating margin guidance appears aggressive. We also conclude that with the expected moderation of revenue contribution from PRXL's largest client, upside to FY14 revenue guidance may be limited. Downgrading to Underperform and establishing a $36 price target based on 16x our CY15 EPS estimate of $2.36.”

PAREXEL closed on Tuesday at $51.33.

Latest Ratings for PRXL

DateFirmActionFromTo
May 2015JefferiesMaintainsHold
Apr 2015JefferiesMaintainsHold
Mar 2015SunTrust Robinson HumphreyMaintainsNeutral

View More Analyst Ratings for PRXL
View the Latest Analyst Ratings

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Downgrades Analyst Ratings

 

Related Articles (PRXL)

Around the Web, We're Loving...